Evidence map›Paper›PMID 42151697›Full record

ArticleMetabolic brain disease2026

Resveratrol as a potential natural compound to ameliorate cognitive impairment in aluminum-exposed mice: impacts on behavior, purinergic system, and brain inflammation.

Alice Estivalet Visentini, Karine Paula Reichert, Maria Rosa Chitolina Schetinger, Nathieli Bianchin Bottari, Vanessa Valéria Miron, Milagros Fanny Vera Castro, Marcylene Vieira da Silveira, Charles Elias Assmann, Adriel Antonio Schirmann, Vera Maria Melchiors Morsch

Abstract read
In one paragraph

Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alice Estivalet VisentiniPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil. Visentini.alice@acad.ufsm.br.ORCID 0009-0004-4559-4807
Karine Paula ReichertPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Maria Rosa Chitolina SchetingerPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.ORCID 0000-0002-5240-8935
Nathieli Bianchin BottariPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Vanessa Valéria MironPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Milagros Fanny Vera CastroPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Marcylene Vieira da SilveiraPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Charles Elias AssmannPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Adriel Antonio SchirmannPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Vera Maria Melchiors MorschPostGraduate Program in Toxicological Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.ORCID 0000-0002-5381-4556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aluminum (Al³⁺) accumulates in the brain and has been linked to neurodegeneration. When combined with citrate, its absorption increase, raising the risk of neurodegenerative disorders such as Alzheimer’s disease. Resveratrol (RSV), a polyphenol with anti-inflammatory, antioxidant, and neuroprotective properties, has been associated with aging prevention by reducing oxidative stress. This in vivo study aimed to determine whether RSV could protect male Swiss mice from Al³⁺-induced cognitive impairment, alterations in purinergic signaling, and brain inflammation. The study was conducted using 60 animals treated with aluminum chloride (AlCl₃ 50 mg/Kg, gavage), citrate (AlCl₃ 50 mg/Kg + CIT 100 mg/Kg, gavage), and resveratrol (AlCl₃ 50 mg/Kg + RSV 100 mg/Kg, gavage), along with their respective Controls, for 30 days every 48 h. Behavioral assessments included the open field test, object recognition test, and Y-maze test to evaluate cognitive performance. Enzymatic activity of purinergic pathways and levels of receptors and inflammation-related molecules were also analyzed. AlCl₃ and AlCl₃ + CIT induced an inflammatory response in mice, as evidenced by the modulation of purinergic system enzymes associated with inflammation. Al³⁺ intoxication also triggered behavior alterations, which was modulated by CIT and alleviated by RSV treatment. Western blot findings revealed that AlCl₃ and AlCl₃ + CIT altered protein levels of purinergic receptors (A1R, A2AR, and P2 × 7R), the inflammasome protein NLRP3, the pro-inflammatory cytokine IL-1β, and the neurotrophic factor BDNF. RSV counteracted the toxic effects of Al³⁺, providing neuroprotection against its toxicity and presenting itself as a potential therapeutic candidate for cognitive deficits.

Indexed as

AluminumBehavior, AnimalCognitive DysfunctionEncephalitisNeuroprotective AgentsReceptors, PurinergicResveratrolAluminum ChlorideAluminum CompoundsAnimalsAntioxidantsBrainMaleMaze LearningMiceAluminumAluminum ChlorideAluminum CompoundsAntioxidantsNeuroprotective AgentsReceptors, PurinergicResveratrolAlzheimer’s diseaseAntioxidantBDNFBehavior assessmentNeurodegeneration

Identifiers

PMID42151697
PMCPMC13183731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.